Aerie's Rhopressa meets in modified Phase III study

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $13.65 (76%) to $31.65 in after-hours trading Wednesday after it said Rhopressa ( AR-13324) met the primary endpoint in a top-line analysis of the Rocket 2 Phase III trial to treat glaucoma. In June, FDA had allowed the company to modify the primary endpoint of Rocket 2.

Aerie said both once and twice daily doses of Rhopressa showed non-inferiority to timolol in reducing intraocular pressure in glaucoma patients with baseline intraocular pressures (IOP) of 20-25 mmHg. Once daily Rhopressa missed the secondary endpoint of reducing IOP in patients with a baseline IOP of <27 mmHg; the twice daily dose met the endpoint. ...